ADMP Adamis Pharmaceuticals Corp
- Pharmaceutical Preparation Manufacturing
15 minute delayed price. Price provided by IEX Cloud. The content contained therein is being provided to you for informational purposes only, does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and does not constitute a recommendation by GoScour to buy, sell, or hold any security, financial product, or instrument referenced in the content. GoScour is not liable for any errors or delays in content, or for any actions taken in reliance on any content.
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements